A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors

NCT04501770 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-Positive Solid Tumors

Interventions

DRUG: Chort 1 of M802
DRUG: Chort 2 of M802
DRUG: Cohort 3 of M802
DRUG: Cohort 4 of M802
DRUG: Cohort 5 of M802
DRUG: Cohort 6 of M802
DRUG: Cohort 7 of M802
DRUG: Cohort 8 of M802

Sponsor

Wuhan YZY Biopharma Co., Ltd.